These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


1992 related items for PubMed ID: 18157145

  • 21. Concurrent delivery of GM-CSF and endostatin genes by a single adenoviral vector provides a synergistic effect on the treatment of orthotopic liver tumors.
    Tai KF, Chen PJ, Chen DS, Hwang LH.
    J Gene Med; 2003 May; 5(5):386-98. PubMed ID: 12731087
    [Abstract] [Full Text] [Related]

  • 22. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
    Liu TC, Wang Y, Hallden G, Brooks G, Francis J, Lemoine NR, Kirn D.
    Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
    [Abstract] [Full Text] [Related]

  • 23. Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice.
    Su C, Peng L, Sham J, Wang X, Zhang Q, Chua D, Liu C, Cui Z, Xue H, Wu H, Yang Q, Zhang B, Liu X, Wu M, Qian Q.
    Mol Ther; 2006 May; 13(5):918-27. PubMed ID: 16497559
    [Abstract] [Full Text] [Related]

  • 24. Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition.
    Yoo JY, Kim JH, Kim J, Huang JH, Zhang SN, Kang YA, Kim H, Yun CO.
    Gene Ther; 2008 May; 15(9):635-51. PubMed ID: 18273054
    [Abstract] [Full Text] [Related]

  • 25. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
    Li Y, Yu DC, Chen Y, Amin P, Zhang H, Nguyen N, Henderson DR.
    Cancer Res; 2001 Sep 01; 61(17):6428-36. PubMed ID: 11522637
    [Abstract] [Full Text] [Related]

  • 26. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
    Irving J, Wang Z, Powell S, O'Sullivan C, Mok M, Murphy B, Cardoza L, Lebkowski JS, Majumdar AS.
    Cancer Gene Ther; 2004 Mar 01; 11(3):174-85. PubMed ID: 14726958
    [Abstract] [Full Text] [Related]

  • 27. [Construction of a new oncolytic virus oHSV2hGM-CSF and its anti-tumor effects].
    Shi GL, Zhuang XF, Han XP, Li J, Zhang Y, Zhang SR, Liu BL.
    Zhonghua Zhong Liu Za Zhi; 2012 Feb 01; 34(2):89-95. PubMed ID: 22780924
    [Abstract] [Full Text] [Related]

  • 28. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
    Lee YS, Kim JH, Choi KJ, Choi IK, Kim H, Cho S, Cho BC, Yun CO.
    Clin Cancer Res; 2006 Oct 01; 12(19):5859-68. PubMed ID: 17020994
    [Abstract] [Full Text] [Related]

  • 29. Combination gene therapy of lung cancer with conditionally replicating adenovirus and adenovirus-herpes simplex virus thymidine kinase.
    Oh JY, Park MY, Kim DR, Lee JH, Shim SH, Chung JH, Yoon HI, Lee JH, Sung MW, Kim YS, Lee CT.
    Int J Mol Med; 2010 Mar 01; 25(3):369-76. PubMed ID: 20127041
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Adenoviral oncolytic suicide gene therapy for a peritoneal dissemination model of gastric cancer in mice.
    Imamura Y, Ishikawa S, Sato N, Karashima R, Hirashima K, Hiyoshi Y, Nagai Y, Koga Y, Hayashi N, Watanabe M, Yamada G, Baba H.
    Ann Surg Oncol; 2010 Feb 01; 17(2):643-52. PubMed ID: 20012217
    [Abstract] [Full Text] [Related]

  • 34. Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy.
    Bernt KM, Ni S, Tieu AT, Lieber A.
    Cancer Res; 2005 May 15; 65(10):4343-52. PubMed ID: 15899826
    [Abstract] [Full Text] [Related]

  • 35. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene.
    Cao X, Yang M, Wei RC, Zeng Y, Gu JF, Huang WD, Yang DQ, Li HL, Ding M, Wei N, Zhang KJ, Xu B, Liu XR, Qian QJ, Liu XY.
    Gene Ther; 2011 Aug 15; 18(8):765-77. PubMed ID: 21412282
    [Abstract] [Full Text] [Related]

  • 36. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor.
    Cho WK, Seong YR, Lee YH, Kim MJ, Hwang KS, Yoo J, Choi S, Jung CR, Im DS.
    Mol Ther; 2004 Nov 15; 10(5):938-49. PubMed ID: 15509511
    [Abstract] [Full Text] [Related]

  • 37. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
    Kohno SI, Luo C, Nawa A, Fujimoto Y, Watanabe D, Goshima F, Tsurumi T, Nishiyama Y.
    Cancer Gene Ther; 2007 Nov 15; 14(11):918-26. PubMed ID: 17693992
    [Abstract] [Full Text] [Related]

  • 38. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
    Wohlfahrt ME, Beard BC, Lieber A, Kiem HP.
    Cancer Res; 2007 Sep 15; 67(18):8783-90. PubMed ID: 17875719
    [Abstract] [Full Text] [Related]

  • 39. Tumor-selective replication of an oncolytic adenovirus carrying oct-3/4 response elements in murine metastatic bladder cancer models.
    Wu CL, Shieh GS, Chang CC, Yo YT, Su CH, Chang MY, Huang YH, Wu P, Shiau AL.
    Clin Cancer Res; 2008 Feb 15; 14(4):1228-38. PubMed ID: 18281558
    [Abstract] [Full Text] [Related]

  • 40. Oncolytic adenovirus delivering herpes simplex virus thymidine kinase suicide gene reduces the growth of human retinoblastoma in an in vivo mouse model.
    Ji X, Zhang J, Cheng L, Wei F, Li H, Liu X, Chen X, Li C, Wang Y, Huang Q.
    Exp Eye Res; 2009 Aug 15; 89(2):193-9. PubMed ID: 19328781
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 100.